Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Authors
Keywords
-
Journal
Molecular Metabolism
Volume 63, Issue -, Pages 101533
Publisher
Elsevier BV
Online
2022-07-07
DOI
10.1016/j.molmet.2022.101533
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls
- (2022) Lotte Simonsen et al. PLoS One
- The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
- (2021) Qian Zhang et al. Cell Metabolism
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- The therapeutic potential of GLP‐1 receptor biased agonism
- (2021) Ben Jones BRITISH JOURNAL OF PHARMACOLOGY
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
- (2021) Julie R. Lundgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- 104-OR: Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects
- (2021) SHWETA URVA et al. DIABETES
- 679-P: The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes
- (2021) TAMER COSKUN et al. DIABETES
- GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist Induced Nausea and Emesis in Preclinical Models
- (2021) Tito Borner et al. DIABETES
- Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
- (2021) Rajaa Nahra et al. DIABETES CARE
- Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling
- (2021) Ville Karhunen et al. DIABETOLOGIA
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity
- (2021) Parsa Akbari et al. SCIENCE
- Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
- (2021) Juan P Frías et al. Lancet Diabetes & Endocrinology
- Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
- (2021) Martin Bossart et al. Cell Metabolism
- GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists
- (2020) Jens Juul Holst et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Drug Therapy in Obesity: A Review of Current and Emerging Treatments
- (2020) David M. Williams et al. Diabetes Therapy
- How May GIP Enhance the Therapeutic Efficacy of GLP-1?
- (2020) Ricardo J. Samms et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
- (2020) Francis S. Willard et al. JCI Insight
- The mediation by GLP-1 receptors of glucagon-induced insulin secretion revisited in GLP-1 receptor knockout mice
- (2020) Bo Ahrén et al. PEPTIDES
- Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
- (2020) Elizabeth A. Killion et al. Nature Communications
- Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes
- (2020) Olof Eriksson et al. Scientific Reports
- Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis
- (2020) Marie Winther-Sørensen et al. Molecular Metabolism
- Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities
- (2019) Jonas Petersen et al. DRUGS
- Glucagon, GLP-1 and Thermogenesis
- (2019) Ismael González-García et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Glucagon Regulation of Energy Expenditure
- (2019) Maximilian Kleinert et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy, safety, and mechanistic insights of cotadutide a dual receptor glucagon-like peptide-1 and glucagon agonist
- (2019) Victoria E R Parker et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates
- (2019) Patrick J. Knerr et al. PEPTIDES
- Dual glucagon‐like peptide‐1 receptor/glucagon receptor agonist SAR425899 improves beta‐cell function in type 2 diabetes
- (2019) Roberto Visentin et al. DIABETES OBESITY & METABOLISM
- An overview of GLP-1 agonists and recent cardiovascular outcomes trials
- (2019) Kelsey H Sheahan et al. POSTGRADUATE MEDICAL JOURNAL
- Optimization of peptide-based polyagonists for treatment of diabetes and obesity
- (2018) Patrick J. Knerr et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Glucagon-receptor Signaling Regulates Energy Metabolism Via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21
- (2018) Teayoun Kim et al. DIABETES
- Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
- (2018) Bo Ahrén et al. DIABETES OBESITY & METABOLISM
- Targeting the Incretin/Glucagon System with Triagonists to Treat Diabetes
- (2018) Megan E Capozzi et al. ENDOCRINE REVIEWS
- Hemodynamic Effects of Glucagon: A Literature Review
- (2018) Kasper Meidahl Petersen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- Combination Therapies for Obesity
- (2018) Michael Camilleri et al. Metabolic Syndrome and Related Disorders
- A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
- (2018) Joachim Tillner et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Anti-Obesity Therapy: from Rainbow Pills to Polyagonists
- (2018) T. D. Müller et al. PHARMACOLOGICAL REVIEWS
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
- (2018) Elizabeth A. Killion et al. Science Translational Medicine
- Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
- (2018) Piotr A. Mroz et al. Molecular Metabolism
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
- (2018) Tamer Coskun et al. Molecular Metabolism
- Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
- (2016) Matthias H. Tschöp et al. Cell Metabolism
- Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
- (2016) S. J. Henderson et al. DIABETES OBESITY & METABOLISM
- Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials
- (2016) Karolin Bettge et al. DIABETES OBESITY & METABOLISM
- Reappraisal of GIP Pharmacology for Metabolic Diseases
- (2016) Brian Finan et al. TRENDS IN MOLECULAR MEDICINE
- Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
- (2015) V. Salem et al. DIABETES OBESITY & METABOLISM
- The New Era of Drug Therapy for Obesity: The Evidence and the Expectations
- (2015) Ben J. Jones et al. DRUGS
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
- (2015) Jesper Lau et al. JOURNAL OF MEDICINAL CHEMISTRY
- GLP-1 and Glucose Tolerance After Sleeve Gastrectomy in Morbidly Obese Subjects With Type 2 Diabetes
- (2014) A. Jimenez et al. DIABETES
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
- (2014) Brian Finan et al. NATURE MEDICINE
- Cardiovascular and hemodynamic effects of glucagon-like peptide-1
- (2014) Adam G. Goodwill et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
- (2013) B. Finan et al. Science Translational Medicine
- Peptide lipidation stabilizes structure to enhance biological function
- (2013) Brian P. Ward et al. Molecular Metabolism
- Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents
- (2012) Jonathan W. Day et al. BIOPOLYMERS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More